His-tag ELISA for the Detection of Humoral Tumor-Specific Immunity

Goodell, Vivian; McNeel, Douglas G.; Nguyen, Lillian; Cardon, K; Disis, Mary L.

doi:10.1097/00002371-200411000-00148

Cited by 2 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(15) For murine serum samples, the same protocol was used except for the following substitutions: purified mouse recombinant IGFBP-2 protein (Sigma) and anti-mouse IgG/HRP conjugate (Zymed Laboratories). IGFBP-2 antibody immunity detected by ELISA was verified using Western blot analysis.…”

Section: Methodsmentioning

confidence: 99%

Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer

et al. 2008

Self Cite

View full text Add to dashboard Cite

Breast cancer is immunogenic and well suited to treatment via immunomodulation. The disease is often treated to remission and time to relapse is generally measured in years in many cases. Immune-based therapeutics, such as cancer vaccines, may be able to affect the clinical progression of micrometastatic disease. Immune targets must be identified that have the potential to inhibit tumor growth. Insulin-like growth factor-binding protein-2 (IGFBP-2) has direct effects on breast cancer proliferation via stimulation of critical signaling pathways. We questioned whether IGFBP-2 was an immune target in breast cancer. IGFBP-2-specific IgG antibody immunity was preferentially detected in breast cancer patients compared with controls (P = 0.0008). To evaluate for the presence of T-cell immunity, we identified potential pan-HLA-DR binding epitopes derived from IGFBP-2 and tested the peptides for immunogenicity. The majority of epitopes elicited peptide-specific T cells in both patients and controls and had high sequence homology to bacterial pathogens. IGFBP-2 peptide-specific T cells could respond to naturally processed and presented IGFBP-2 protein, indicating that these peptides were native epitopes of IGFBP-2. Finally, both immunization with IGFBP-2 peptides as well as adoptive transfer of IGFBP-2-competent T cells mediated an antitumor effect in a transgenic mouse model of breast cancer. This is the first report of IGFBP-2 as a human tumor antigen that may be a functional therapeutic target in breast cancer. [Cancer Res 2008;68(20):8400-9]

show abstract

Section: Methodsmentioning

confidence: 99%

Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…Goodell et al [43] demonstrated by specifically designed his-tagged capture ELISA (based on lysate from genetically engineered Chinese hamster ovary cells) the presence of AAbs to IGFBP-2 in the sera of 4/80 (5%) breast carcinoma patients, 32/80 (40%) colorectal carcinoma patients and 2/200 (1%) healthy controls. These corresponded to a significant difference between all carcinoma patients and healthy controls ( P = .008), between breast carcinoma patients and healthy controls ( P = .032), and between colorectal carcinoma patients and healthy controls ( P < .001) [43]. The authors concluded that the AAbs to IGFBP-2 assayed by capture ELISA can discriminate between cancer patients and controls [43].…”

Section: Autoantibodies To Insulin-like Growth Factor Binding Promentioning

confidence: 99%

“…These corresponded to a significant difference between all carcinoma patients and healthy controls ( P = .008), between breast carcinoma patients and healthy controls ( P = .032), and between colorectal carcinoma patients and healthy controls ( P < .001) [43]. The authors concluded that the AAbs to IGFBP-2 assayed by capture ELISA can discriminate between cancer patients and controls [43]. It seems, however, that AAbs to IGFBP-2 have little value for screening and early diagnosis of breast carcinoma when examined alone.…”

Section: Autoantibodies To Insulin-like Growth Factor Binding Promentioning

confidence: 99%

Autoantibodies to Tumor-Associated Antigens in Breast Carcinoma

Piura

2010

Journal of Oncology

View full text Add to dashboard Cite

Autoantibodies (AAbs) to tumor-associated antigens (TAAs) have been identified in the circulation of patients with cancer. This paper will focus on recent knowledge related to circulating AAbs to TAAs in breast carcinoma. So far, the following TAAs have been identified to elicit circulating AAbs in breast carcinoma: p53, MUC-1, heat shock proteins (HSP-27, HSP-60, and HSP-90), HER2/neu/c-erb B2, GIPC-1, c-myc, c-myb, cancer-testis antigens (NY-ESO-1), BRCA1, BRCA2, endostatin, lipophilin B, cyclin B1, cyclin D1, fibulin, insulin-like growth factor binding protein 2 (IGFBP-2), topoisomerase II alpha (TOPO2α), and cathepsin D. Measurement of serum AAbs to one specific TAA only is of little value for screening and early diagnosis of breast carcinoma; however, assessment of AAbs to a panel of TAAs may have promising diagnostic potential.

show abstract

His-tag ELISA for the Detection of Humoral Tumor-Specific Immunity

Cited by 2 publications

References 6 publications

Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer

Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer

Autoantibodies to Tumor-Associated Antigens in Breast Carcinoma

Contact Info

Product

Resources

About